Abemaciclib is in a class of medications called kinase inhibitors.
FREE CLINICAL TRIALS FOR PROSTATE HEALTH TRIAL
This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). The purpose of this study is to find out the effects ZEN-3694, enzalutamide, and pembrolizumab on patients with metastatic castration-resistant prostate cancer who have previously experienced disease progression. It also enhances the activity of the body's immune cells against tumor cells. Pembrolizumab is a monoclonal antibody (proteins that can protect the body from foreign organisms, such as bacteria and viruses) designed to block a specific control switch which may be activated by tumor cells to overcome the body's natural immune system defenses. When enzalutamide (key) inserts into the androgen receptor (lock) testosterone cannot attach to the androgen receptor, which slows the growth of tumor cells and may cause them to shrink. Enzalutamide has been shown to block testosterone from reaching prostate cancer cells by binding to a receptor on prostate cancer cells, called androgen receptors. ZEN-3694 blocks the expression of the MYC gene to prevent cellular growth in certain types of tumors, including castrate resistant prostate cancer. This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). San Francisco, California and other locations If participants cancer returns, they will have repeat PET/CT scans. They will have 5 visits the first year and 2 the second. After surgery, participants will have follow-up visits for 5 years.
If the PET/CT scan suggests the cancer has spread, participants may need to have another biopsy within 60 days after the scan. Some tissue will be used for genetic testing. This will remove the prostate gland and lymph nodes around it. Within 60 days after the scan, participants will have surgery. During the scan, they will lie on their back and stay still. They will have a PET/CT scan of their whole body 60 90 minutes later. Bone scan Participants will have a radiotracer injected into a vein. The machine will take pictures of the body. Eligibility: Men ages 18 and older with prostate cancer that appears to be contained within the prostate but is at risk of having spread Design: Participants will be screened with: - Medical history - Blood tests - CT and MRI scans: Participants will lie in a machine.
Also, to test if this approach is better or worse than the usual approach for prostate cancer. Objective: To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. They then have their prostate gland removed. Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan.